In the news
In the news
Press Releases
01-20-2025
Leaps by Bayer Publishes Breakthrough Study in Collaboration with BCG
Read10-24-2024
Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program
Read05-28-2024
Bayer advances genome-editing initiatives for nutrition enhanced vegetables
Read02-13-2024
Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
Read01-06-2024
Bayer and RTW Investments lead Series D financing in Chinese biotech Ji Xing Pharmaceuticals
Read
Press coverage of Leaps and portfolio companies
Leaps events
Spotlight on Juergen Eckhardt
Juergen Eckhardt is EVP and Head of Leaps by Bayer, the impact investment arm, and Head of Business Development, & Licensing (BD&L) for the Pharmaceuticals division. He is a medical doctor and venture investor in healthcare, biotech, and agriculture with more than 20 years of experience. He is a strong believer that scientific breakthroughs can help us overcome some of humanity’s biggest challenges, including to cure and prevent chronic disease and to feed an ever-growing world population in a sustainable way – in short: science for a better life. He holds an MD from the University of Basel, Switzerland, and an MBA from INSEAD in Fontainebleau, France.
Read More
Op-eds by Juergen Eckhardt
- Read More
February 18, 2025
New Global Survey Reveals Mixed Attitudes Toward Breakthrough Tech
- Read More
January 16, 2025
5 Insights From The 2025 JP Morgan Healthcare Conference
- Read More
December 19, 2024
5 Important Medical Breakthroughs Of 2024
- Read More
December 12, 2024
Fiber Is Key To Health. Clever New Tech Wants To Help You Get Enough
- Read More
November 26, 2024
This Carbon-Negative Biofuel Might Ultimately Replace Coal
- Read More
November 13, 2024
3 Ways The New Administration Could Speed The Path To New Medicines
Reports
Explore the latest reports and publications developed by Leaps by Bayer and our collaborators.
Find out how people in the US feel about breakthrough science in our Breakthrough Study Snapshot Report, a collaboration with BCG and market research by IPSOS.
Download
Find out how people around the world feel about breakthrough science in our Breakthrough Study, a collaboration with BCG and market research by IPSOS.
Download
Read about our 2024 milestones, portfolio company highlights, engagement activities, and more.
Download
Learn about our custom impact measurement framework WALY and read about the impact magnitude of our portfolio.
Download
Learn how to bring AgTech products from concept to market.
Download
Read about our 2023 milestones, portfolio company highlights, engagement activities, and more.
Download
See how our 10 Leaps framework could generate return for humanity.
Download
Read about our 2022 milestones, portfolio company highlights, engagement activities, and more.
Download
Press Kit
Leaps by Bayer is the impact investment arm of Bayer AG. We invest in teams pursuing fundamental breakthroughs in life science, targeting 10 huge challenges facing humanity.
Some call them impossible. We call them “Leaps”.
Media Contact
Kira Peikoff
Kira Peikoff is a former journalist who covered emerging biotechnologies for publications including The New York Times, Newsweek, and Popular Mechanics. She now leads communications for Leaps by Bayer.
Our return to humanity
The Leaps team brings together a diverse group of individuals with expertise in biotech, healthcare, agriculture, investment, and communication.